β图谱:非常规β⁻发射体用于靶向放射性药物治疗的全球生产图景(第一部分)
该综述聚焦已进入临床评估的非常规β⁻发射体(67Cu、153Sm、161Tb、166Ho、186Re、188Re),系统梳理其全球生产中心现状与临床评价进展。作者指出,这类核素的临床转化仍受生产约束和临床证据不一致的限制,β图谱旨在为研究者、临床医生和产业界提供战略资源,促进合作与投资,推动建立更可靠、可扩展的供应链。
要点
- 聚焦67Cu、153Sm、161Tb、166Ho、186Re、188Re六种已进入临床评估的非常规β⁻发射体。
- 临床转化受生产约束和临床证据不一致限制。
- β图谱旨在指导合作与投资,强化非常规β⁻发射体供应链。
核心结论
- 非常规β⁻发射体的临床转化仍受生产约束和临床证据不一致的限制,β图谱可为整合替代β⁻发射体进入临床实践提供战略参考。
研究设计与样本
- 综述报告非常规β⁻发射体生产的最新进展、全球生产中心格局,并回顾当前临床评价。
主要发现
- β图谱聚焦已进入临床评估的β⁻发射体,包括67Cu、153Sm、161Tb、166Ho、186Re和188Re。
- 对发射谱和诊疗一体化潜力的需求推动非常规β⁻发射体研究扩展。
临床怎么用
- 帮助研究者、临床医生和产业界识别将替代β⁻发射体整合入临床实践的机遇与约束。
- 作为战略资源促进合作并引导投资流向更可靠、可扩展的非常规β⁻发射体供应链。
局限性
- 非常规β⁻发射体的临床转化受生产约束和临床证据不一致的限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
β-minus particle (β-)-emitting radionuclides have long been central to targeted radiopharmaceutical therapy. Interest in expanding their repertoire beyond conventional options has grown over time, as the need for radionuclides with different emission profiles and theranostic potential becomes increasingly clear. Nonetheless, their clinical translation remains limited by production constraints, inconsistent clinical evidence supporting their use. By reporting the state of the art in nonconventional β--radionuclide production, the current global landscape of production centers and reviewing current clinical evaluations, this β-atlas provides a critical overview of how these radionuclides may influence the future of targeted radiopharmaceutical therapy. This perspective is intended to support researchers, clinicians, and industry in recognizing both the opportunities and the constraints associated with integrating alternative β--emitters into clinical practice. Ultimately, this β-atlas aims to serve as a strategic resource to foster collaboration and guide investment toward more reliable and scalable supply chains of nonconventional β--emitters, thereby strengthening the foundation for future innovation in β--based therapy. This review focuses on β--emitters that have already progressed to clinical evaluation, including 67Cu, 153Sm, 161Tb, 166Ho, 186Re, and 188Re.
引用
- Tosato M, Kleynhans J, van de Voorde M, et al. Beta Atlas: Charting Global Production of Nonconventional β--Emitters for Targeted Radiopharmaceutical Therapy-Part 1. J Nucl Med. 2026. PMID: 42754345. doi:10.2967/jnumed.126.272648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。